Edgewise Therapeutics, Inc.·4

Aug 18, 7:13 PM ET

Semigran Marc 4

4 · Edgewise Therapeutics, Inc. · Filed Aug 18, 2023

Insider Transaction Report

Form 4
Period: 2023-08-17
Semigran Marc
Chief Development Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2023-08-17+133,333133,333 total
    Exercise: $7.08Exp: 2033-08-17Common Stock (133,333 underlying)
Footnotes (1)
  • [F1]1/48th of the shares subject to the option vest each month beginning on September 17, 2023, subject to the Reporting Person continuing as a service provider through each vest date.

Documents

1 file
  • 4
    primarydocument.xmlPrimary

    PRIMARY DOCUMENT